Candel Therapeutics (CADL) News Today → How this is some devastating news (From WealthPress) (Ad) Free CADL Stock Alerts $11.50 -1.20 (-9.45%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 12:04 AM | markets.businessinsider.comCandel Lights Up Investors' Portfolio With 830% GainMay 14, 2024 | investorplace.comCADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024May 14, 2024 | finance.yahoo.comCandel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 14, 2024 | globenewswire.comCandel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 11, 2024 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest UpdateCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 1,050,000 shares, a decrease of 48.3% from the April 15th total of 2,030,000 shares. Currently, 6.7% of the shares of the stock are sold short. Based on an average trading volume of 5,290,000 shares, the short-interest ratio is currently 0.2 days.April 25, 2024 | globenewswire.comCandel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingApril 15, 2024 | seekingalpha.comCandel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic CancerApril 15, 2024 | marketbeat.comShort Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 9.2%Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 160,900 shares, an increase of 9.2% from the March 15th total of 147,300 shares. Currently, 1.0% of the company's shares are short sold. Based on an average daily trading volume, of 3,880,000 shares, the days-to-cover ratio is currently 0.0 days.April 11, 2024 | markets.businessinsider.comCandel Therapeutics' CAN-2409 For Pancreatic Cancer Gets FDA Orphan Drug Designation; Stock UpApril 11, 2024 | markets.businessinsider.comWhy Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionApril 11, 2024 | marketwatch.comCandel Therapeutics Shares Leap Premarket on FDA Orphan-Drug DesignationApril 11, 2024 | globenewswire.comCandel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerApril 9, 2024 | globenewswire.comCandel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsApril 6, 2024 | finance.yahoo.comRetail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewardedApril 5, 2024 | benzinga.comWhat's Going On With Candel Therapeutics Stock On Friday?April 5, 2024 | msn.comCandel Therapeutics stock jumps as pancreatic cancer treatment shows promiseApril 5, 2024 | marketbeat.comTrading was temporarily halted for "CADL" at 12:04 PM with a stated reason of "LULD pause." Trading set to resume at 12:04 PM. April 5, 2024 | marketbeat.comTrading was temporarily halted for "CADL" at 11:04 AM with a stated reason of "LULD pause."April 5, 2024 | marketbeat.comTrading was temporarily halted for "CADL" at 10:04 AM with a stated reason of "LULD pause."April 5, 2024 | marketbeat.comTrading was temporarily halted for "CADL" at 10:04 AM with a stated reason of "LULD pause."April 5, 2024 | marketbeat.comTrading was temporarily halted for "CADL" at 09:04 AM with a stated reason of "LULD pause."April 5, 2024 | marketbeat.comUnusually High Volume Points to Upside in These StocksIf investing were easy, everybody would do it, and we would all be rich. But that isn't the case.April 5, 2024 | marketbeat.comUnusually High Volume Points to Upside in These StocksUnusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance.April 4, 2024 | msn.comWhy Allurion Technologies Stock Is Racing HigherApril 4, 2024 | investing.comAfter-hours movers: SoFi Technologies, GameStop, and moreApril 4, 2024 | marketbeat.comTrading was temporarily halted for "CADL" at 03:04 PM with a stated reason of "LULD pause."April 4, 2024 | marketwatch.comCandel Therapeutics Shares Hit 52-Week High After Positive Trial DataApril 4, 2024 | markets.businessinsider.comCandel's CAN-2409 Shows Positive Trial Results In Non-Metastatic Pancreatic Cancer; Stock UpApril 4, 2024 | finance.yahoo.comAfter Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer StudyApril 4, 2024 | globenewswire.comCandel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerApril 1, 2024 | msn.comMicro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor ImmunotherapyMarch 28, 2024 | globenewswire.comCandel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaMarch 28, 2024 | investorplace.comCADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023March 28, 2024 | benzinga.comRecap: Candel Therapeutics Q4 EarningsMarch 28, 2024 | globenewswire.comCandel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 5, 2024 | globenewswire.comCandel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateFebruary 21, 2024 | benzinga.comCandel Therapeutics Stock (NASDAQ:CADL), Short Interest ReportFebruary 15, 2024 | marketbeat.comShort Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Declines By 10.9%Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 166,200 shares, a drop of 10.9% from the January 15th total of 186,600 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily volume of 537,800 shares, the short-interest ratio is presently 0.3 days.February 13, 2024 | markets.businessinsider.comCandel's Can-3110 Receives FDA Fast Track DesignationFebruary 13, 2024 | finanznachrichten.deCandel Therapeutics: CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaFebruary 13, 2024 | benzinga.comCandel Therapeutics Sets Stage For Success With Cancer-Fighting ImmunotherapiesFebruary 13, 2024 | msn.comKrystal Biotech, Candel, Edgewise gain after FDA fast track tagsFebruary 13, 2024 | finance.yahoo.comCAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaFebruary 5, 2024 | finance.yahoo.comCandel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsDecember 13, 2023 | finance.yahoo.comCandel (CADL) Rises on FDA's Fast Track Status for CAN-2409December 13, 2023 | marketwatch.comCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409December 12, 2023 | markets.businessinsider.comCandel Receives FDA Fast Track Designation For CAN-2409 Plus ProdrugDecember 12, 2023 | finance.yahoo.comCandel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNovember 29, 2023 | msn.comCandel downsizes to focus on oncolytic virus-based cancer therapiesNovember 28, 2023 | bizjournals.comImmuno-oncology firm Candel cuts its workforce in half Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Free report reveals “two-baggers” for 2024 (Ad)We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable. Download your free report today! CADL Media Mentions By Week CADL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼0.470.42▲Average Medical News Sentiment CADL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼51▲CADL Articles Average Week Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: JSPR News Today BDTX News Today URGN News Today SOPH News Today CRBU News Today MGTX News Today IVVD News Today ADAP News Today TNYA News Today PSTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
